More on REGn
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $819.09 |
|
|||
| Open | $819.09 | ||||
| 52 Wk High | $592.36 | ||||
| 52 Wk Low | $325.35 | ||||
| Day High | $819.09 | ||||
| Day Low | $801.22 | ||||
| P/E | 211.29 | ||||
| EPS | $3.81 | ||||
| Volume | 527,740 | ||||
- Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
- Regeneron Pharma (REGN) PT Raised to $980 at TD Cowen
- Regeneron Pharma (REGN) PT Raised to $865 at Piper Sandler
- EU panel backs updated Libtayo dosing schedule for all cancer types
- Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
- Form 4 REGENERON PHARMACEUTICAL For: Oct 13 Filed by: MURPHY ANDREW J
- Form 144 REGENERON PHARMACEUTICAL Filed by: MURPHY ANDREW J
- Regeneron's Pasatru shows no new bone lesions at 84 weeks in FOP trial
- Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
- Regeneron Pharma (REGN) PT Raised to $810 at RBC Capital
Entities mentioned with REGn
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
